T1	Investigation 15 93	Currently clinical trials are being carried out using recombinant human IL-10.
A1	Source T1 General_reference
T2	Source_cue 25 40	clinical trials
R1	Cue Arg1:T2 Arg2:T1	
T3	KT_cue 25 62	clinical trials are being carried out
R2	Cue Arg1:T3 Arg2:T1	
T4	Investigation 94 303	These clinical trials have targeted diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, organ transplantation, and chronic hepatitis (Mocellin et al., 2003), (Asadullah et al,. 1999).
A2	Multiple_sources T4
T5	Source_cue 253 303	(Mocellin et al., 2003), (Asadullah et al,. 1999).
R3	Cue Arg1:T5 Arg2:T4	
T6	KT_cue 94 129	These clinical trials have targeted
R4	Cue Arg1:T6 Arg2:T4	
T7	Investigation 304 402	Clinical trials yet need to be conducted to investigate IL-10 and its impact during heart failure.
A3	Source T7 Averred
T14	Analysis 596 735	The findings from these studies, collectively have raised questions if IL-10 expression could reduce pathological hypertrophy in the heart.
T15	KT_cue 664 696	if IL-10 expression could reduce
R10	Cue Arg1:T15 Arg2:T14	
A7	Source T14 Averred
A8	Certainty_Level T14 L1
A9	Modality T14
T16	CL_cue 664 696	if IL-10 expression could reduce
R11	Cue Arg1:T16 Arg2:T14	
T17	Modality_cue 664 696	if IL-10 expression could reduce
R12	Cue Arg1:T17 Arg2:T14	
T18	Fact 736 876	Although, the complex nature of the inflammatory response has presented significant challenges to develop effective and targeted treatments.
A10	Source T18 Averred
T19	KT_cue 746 807	the complex nature of the inflammatory response has presented
R13	Cue Arg1:T19 Arg2:T18	
T20	Fact 878 1024	Despite these significant challenges to develop effective and targeted treatments IL-10 therapeutic strategies have grown in the past few decades.
A11	Source T20 Averred
T21	KT_cue 960 999	IL-10 therapeutic strategies have grown
R14	Cue Arg1:T21 Arg2:T20	
T22	Observation 1025 1197	Data extrapolated from the numerous studies have identified IL-10 as a key player in regulating the inflammatory response and slowing down the progression of heart failure,
A12	Source T22 General_reference
T23	Source_cue 1048 1068	the numerous studies
R15	Cue Arg1:T23 Arg2:T22	
T24	KT_cue 1025 1084	Data extrapolated from the numerous studies have identified
R16	Cue Arg1:T24 Arg2:T22	
T25	Analysis 1198 1402	although it is still unclear whether there is a direct effect of IL-10 via activation of the receptor in cardiomyocytes or whether the effect is secondary due to the reduction of an inflammatory response.
A13	Source T25 Averred
A14	Neg_CL T25
A15	Certainty_Level T25 L1
T26	KT_cue 1207 1226	it is still unclear
R17	Cue Arg1:T26 Arg2:T25	
T27	CL_cue 1207 1226	it is still unclear
R18	Cue Arg1:T27 Arg2:T25	
T28	Investigation 1403 1504	This study is designed to also investigate the direct effect of IL-10 via activation of the receptor.
A16	Source T28 Self_other
T29	KT_cue 1403 1428	This study is designed to
R19	Cue Arg1:T29 Arg2:T28	
T30	Source_cue 1403 1413	This study
R20	Cue Arg1:T30 Arg2:T28	
T31	Fact 1540 1613	Il-10 activity is mediated by its specific cell surface receptor complex.
A17	Source T31 Averred
T32	KT_cue 1540 1569	Il-10 activity is mediated by
R21	Cue Arg1:T32 Arg2:T31	
T33	Fact 1614 1815	IL-10 binds to  the receptor which consists of two identical ligand-binding subunits; IL-10 receptor 1  (IL-10R1)  and IL-10 receptor 2 (IL-10R2) (Donnelly et al., 1999), as demonstrated in Figure 1.5.
A18	Source T33 Non-integral_information_led_citation
T34	KT_cue 1614 1628	IL-10 binds to
R22	Cue Arg1:T34 Arg2:T33	
T35	Source_cue 1760 1784	(Donnelly et al., 1999),
R23	Cue Arg1:T35 Arg2:T33	
T36	Fact 1816 2006	The IL-  10 receptor consists of two different chains, a (Ho et al., 1993) and ? chains (CRFB4) (Kotenko et al., 1997), which are both members of the IFN-y class II cytokine receptor family.
A19	Source T36 Non-integral_information_led_citation
A20	Multiple_sources T36
T37	KT_cue 1816 1848	The IL-  10 receptor consists of
R24	Cue Arg1:T37 Arg2:T36	
T38	Source_cue 1873 1890;1912 1935	(Ho et al., 1993) (Kotenko et al., 1997),
R25	Cue Arg1:T38 Arg2:T36	
T39	Fact 2007 2136	The IFN-y receptor and the IL-10R possess many similarities for example they are both capable of antagonising each other effects.
A21	Source T39 Averred
T40	KT_cue 2007 2048	The IFN-y receptor and the IL-10R possess
R26	Cue Arg1:T40 Arg2:T39	
T41	Fact 2160 2269	The IL-10R1 is ubiquitously expressed on the surface of the cells and is known as the ligand- binding domain.
A22	Source T41 Averred
T42	KT_cue 2160 2197	The IL-10R1 is ubiquitously expressed
R27	Cue Arg1:T42 Arg2:T41	
T43	Observation 2270 2463	Studies have shown IL-10R1 to be expressed in low levels on hematopoietic cells and up-regulated following pathological stimuli on non-hematopoietic cells like fibroblasts and epithelial cells.
A23	Source T43 General_reference
T44	KT_cue 2270 2288	Studies have shown
R28	Cue Arg1:T44 Arg2:T43	
T45	Source_cue 2270 2277	Studies
R29	Cue Arg1:T45 Arg2:T43	
T46	Analysis 2464 2536	The IL-10R2 is mostly expressed on mast cells  and  haematopoietic cells
A24	Source T46 Averred
A25	Certainty_Level T46 L3
T47	KT_cue 2479 2485	mostly
R30	Cue Arg1:T47 Arg2:T46	
T48	CL_cue 2479 2485	mostly
R31	Cue Arg1:T48 Arg2:T46	
T49	Fact 2593 2709	Cardiomyocytes also activate IL-10 receptors, although non-myocytes  constitute the major  source of  the receptors.
A26	Source T49 Averred
T50	KT_cue 2593 2621	Cardiomyocytes also activate
R32	Cue Arg1:T50 Arg2:T49	
T58	Observation 2977 3051	The binding of IL-10 with IL-10R1/ IL-10R2 has recently been characterised
A30	Source T58 Non-integral_information_led_citation
T59	KT_cue 2977 3051	The binding of IL-10 with IL-10R1/ IL-10R2 has recently been characterised
R38	Cue Arg1:T59 Arg2:T58	
T60	Analysis 3052 3106	and seems to be highly complex (Reineke et al., 1999).
A31	Source T60 Non-integral_information_led_citation
A32	Certainty_Level T60 L1
T61	KT_cue 3056 3061	seems
R39	Cue Arg1:T61 Arg2:T60	
T62	Source_cue 3083 3106	(Reineke et al., 1999).
R40	Cue Arg1:T62 Arg2:T60	
T63	CL_cue 3056 3061	seems
R41	Cue Arg1:T63 Arg2:T60	
T64	Fact 3107 3242	The Binding of IL-10 to IL-10R1 and IL-10R2 activate the Signal transducer and activator of transcription 3 (STAT3) signalling pathway,
A33	Source T64 Averred
T65	KT_cue 3107 3159	The Binding of IL-10 to IL-10R1 and IL-10R2 activate
R42	Cue Arg1:T65 Arg2:T64	
T66	Investigation 3243 3308	this is the signalling pathway of interest during this PhD study.
A34	Source T66 Self_other
T67	Source_cue 3286 3308	during this PhD study.
R43	Cue Arg1:T67 Arg2:T66	
T68	KT_cue 3243 3285	this is the signalling pathway of interest
R44	Cue Arg1:T68 Arg2:T66	
T69	Fact 3309 3394	The STAT3 signalling pathway activates the transcription of cytoprotective molecules.
A35	Source T69 Averred
T70	KT_cue 3309 3347	The STAT3 signalling pathway activates
R45	Cue Arg1:T70 Arg2:T69	
T71	Fact 3395 3497	The Binding of IL-10 requires both IL-10R1 and IL-10R2 to activate the downstream signal transduction.
A36	Source T71 Averred
T72	KT_cue 3395 3424	The Binding of IL-10 requires
R46	Cue Arg1:T72 Arg2:T71	
T76	Observation 3681 3856	Spencer  et  al (1998)  found  that the IL-10R-? chain is essential for IL-10-mediated effects and IL-10R- ? deficient mice display the same phenotype as IL-10 deficient mice.
A39	Source T76 Integral_citation
T77	Source_cue 3681 3703	Spencer  et  al (1998)
R49	Cue Arg1:T77 Arg2:T76	
T78	KT_cue 3681 3710	Spencer  et  al (1998)  found
R50	Cue Arg1:T78 Arg2:T76	
T79	Verb_cue 3681 3716	Spencer  et  al (1998)  found  that
R51	Cue Arg1:T79 Arg2:T76	
T80	Observation 3857 3999	Cells that only expressed IL-10R-?, demonstrated that there was no interaction between the IL-10 and IL-10R, resulting in no complexes formed.
A40	Citation_length T80 Extended
A41	Source T80 Integral_citation
T81	KT_cue 3857 3905	Cells that only expressed IL-10R-?, demonstrated
R52	Cue Arg1:T81 Arg2:T80	
A42	Verb_noun T80 Certainty
T82	Verb_cue 3857 3910	Cells that only expressed IL-10R-?, demonstrated that
R53	Cue Arg1:T82 Arg2:T80	
T83	Observation 4000 4120	Spencer et al (1998) found that only cells with  both  the  IL-10Ra and ? chain could activate STAT3 signalling pathway.
A43	Source T83 Integral_citation
A44	Verb_noun T83 Certainty
T84	Source_cue 4000 4020	Spencer et al (1998)
R54	Cue Arg1:T84 Arg2:T83	
T85	Verb_cue 4000 4031	Spencer et al (1998) found that
R55	Cue Arg1:T85 Arg2:T83	
A45	Modality T83
T86	Modality_cue 4032 4094	only cells with  both  the  IL-10Ra and ? chain could activate
R56	Cue Arg1:T86 Arg2:T83	
T90	Fact 4350 4501	IL-10R2 activates Tyk2 and IL-10R1 activates JAK1 which then phosphorylates the cytoplasmic tail of the IL-10R1 enabling the binding of STAT3 molecule.
A47	Source T90 Averred
T91	KT_cue 4350 4367	IL-10R2 activates
R59	Cue Arg1:T91 Arg2:T90	
T92	Fact 4502 4591	Phosphorylation then activates STAT3 which is released from the receptor complex IL-10R1.
A48	Source T92 Averred
T93	KT_cue 4502 4532	Phosphorylation then activates
R60	Cue Arg1:T93 Arg2:T92	
T94	Fact 4592 4771	Once the STAT3 molecule has been dislodged it translocates to the nucleus where it binds to STAT3 binding elements  to  promote various  protective genes  (Donnelly et al., 1999).
A49	Source T94 Non-integral_information_led_citation
T95	KT_cue 4592 4634	Once the STAT3 molecule has been dislodged
R61	Cue Arg1:T95 Arg2:T94	
T96	Source_cue 4747 4771	(Donnelly et al., 1999).
R62	Cue Arg1:T96 Arg2:T94	
T97	Fact 4772 4896	STAT3 induces expression of target genes such as Heme Oxygenase 1 (HO-1) and Tissue Inhibitor of Metalloproteinase (TIMP-3),
A50	Source T97 Non-integral_information_led_citation
T98	KT_cue 4772 4785	STAT3 induces
R63	Cue Arg1:T98 Arg2:T97	
T99	Observation 4897 5009	both genes have shown to have protective properties during hypertrophy (Kunisada et al., 2000) (see figure 1.5).
A51	Source T99 Non-integral_information_led_citation
T100	KT_cue 4897 4921	both genes have shown to
R64	Cue Arg1:T100 Arg2:T99	
T101	Source_cue 4968 4991	(Kunisada et al., 2000)
R65	Cue Arg1:T101 Arg2:T99	
T102	Fact 5010 5170	STAT3 also induces the expression of suppressor of cytokine signalling 3 (SOCS3) which controls the quality and quantity of STAT3 released (Diehl et al., 2002).
A52	Source T102 Non-integral_information_led_citation
T103	KT_cue 5010 5028	STAT3 also induces
R66	Cue Arg1:T103 Arg2:T102	
T104	Source_cue 5149 5170	(Diehl et al., 2002).
R67	Cue Arg1:T104 Arg2:T102	
T105	Observation 5171 5257	SOCS3 has also shown to exert a negative regulatory effect on the different cytokines.
A53	Source T105 Averred
T106	KT_cue 5171 5194	SOCS3 has also shown to
R68	Cue Arg1:T106 Arg2:T105	
T107	Fact 5303 5629	Complex vascular remodelling processes are the substrate and hallmark of vascular diseases like atherosclerosis, post-angioplasty restenosis and pulmonary artery hypertension but are also essential to maintain vascular integrity or to regenerate vascular structures where needed such as during pregnancy (Baines et al., 2005).
A54	Source T107 Non-integral_information_led_citation
T108	KT_cue 5303 5345	Complex vascular remodelling processes are
R69	Cue Arg1:T108 Arg2:T107	
T109	Source_cue 5607 5627	(Baines et al., 2005
R70	Cue Arg1:T109 Arg2:T107	
T110	Fact 5630 5813	Acute and chronic inflammation responses characterize the cardiac hypertrophic remodelling processes in atherosclerosis, restenosis, pulmonary arterial hypertension, and angiogenesis.
A55	Source T110 Averred 
T112	KT_cue 5630 5683	Acute and chronic inflammation responses characterize
R71	Cue Arg1:T112 Arg2:T110	
T113	Fact 5814 6028	The functional, phenotypic changes, Cellular adaption and functional reprogramming in diverse vascular cell types are mediated by various complex signalling cascades that initiate and control genetic reprogramming.
A56	Source T113 Averred
T114	KT_cue 5814 5943	The functional, phenotypic changes, Cellular adaption and functional reprogramming in diverse vascular cell types are mediated by
R72	Cue Arg1:T114 Arg2:T113	
T115	Analysis 6029 6335	The signal transducer and activator of transcription 3 (STAT3) has been extensively described as a central signalling molecule that controls cellular adaption in response to environmental stimuli or stress in endothelial cells, smooth muscle cells and circulating/inflammatory cells (Hattori et al., 2001).
A57	Source T115 Non-integral_information_led_citation
A58	Certainty_Level T115 L3
T116	KT_cue 6029 6125	The signal transducer and activator of transcription 3 (STAT3) has been extensively described as
R73	Cue Arg1:T116 Arg2:T115	
T117	CL_cue 6029 6125	The signal transducer and activator of transcription 3 (STAT3) has been extensively described as
R74	Cue Arg1:T117 Arg2:T115	
T118	Source_cue 6312 6335	(Hattori et al., 2001).
R75	Cue Arg1:T118 Arg2:T115	
T119	Observation 6336 6443	STAT3 has shown to plays a key role in the initiation and continuation of these pathophysiological changes.
A59	Source T119 Averred
T120	KT_cue 6336 6354	STAT3 has shown to
R76	Cue Arg1:T120 Arg2:T119	
T121	Investigation 6444 6696	This study will aims to highlight the pivotal involvement of STAT3 in the pathological cardiac remodelling processes and discusses potential translational therapies, which target STAT3 signalling via IL-10, to prevent and treat cardiovascular diseases.
A60	Source T121 Self_other
T122	Source_cue 6444 6454	This study
R77	Cue Arg1:T122 Arg2:T121	
T123	KT_cue 6444 6467	This study will aims to
R78	Cue Arg1:T123 Arg2:T121	
A61	Source T4 Non-integral_information_led_citation
T124	Fact 6793 6939	The signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, there are seven STAT proteins currently identified,
A62	Source T124 Non-integral_information_led_citation
T125	KT_cue 6793 6858	The signal transducer and activator of transcription 3 (STAT3) is
R79	Cue Arg1:T125 Arg2:T124	
T126	Observation 6940 7048	which have all been found to be expressed in the heart and in cardiomyocytes (Hilfiker-Kleiner et al., 2005)
A63	Source T126 Non-integral_information_led_citation
T127	KT_cue 6940 6968	which have all been found to
R80	Cue Arg1:T127 Arg2:T126	
T128	Source_cue 7017 7048	(Hilfiker-Kleiner et al., 2005)
R81	Cue Arg1:T128 Arg2:T126	
T129	Fact 7049 7158	The STAT family members include; STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 (Santos et al., 2011).
A64	Source T129 Non-integral_information_led_citation
T130	KT_cue 7049 7081	The STAT family members include;
R82	Cue Arg1:T130 Arg2:T129	
T131	Source_cue 7136 7158	(Santos et al., 2011).
R83	Cue Arg1:T131 Arg2:T129	
T132	Analysis 7159 7393	The STAT3 protein has recently emerged as the key co-ordinators to balance the specific pattern of distinct stress signals that are involved in the shift from protective hypertrophy to adverse and detrimental pathological hypertrophy.
A65	Source T132 Averred
T133	KT_cue 7159 7200	The STAT3 protein has recently emerged as
R84	Cue Arg1:T133 Arg2:T132	
T134	Investigation 7394 7534	This PhD project will focus on the STAT3 signalling pathway activated by IL-10 and the effects on the heart during pathological hypertrophy.
A66	Source T134 Self_other
T135	KT_cue 7394 7424	This PhD project will focus on
R85	Cue Arg1:T135 Arg2:T134	
T136	Source_cue 7394 7410	This PhD project
R86	Cue Arg1:T136 Arg2:T134	
T9	Analysis 403 451	Current studies as discussed above indicate that
A4	Verb_noun T9 Likelihood
A5	Source T9 Non-integral_information_led_citation
A6	Certainty_Level T9 L2
T10	Source_cue 403 437;564 595	Current studies as discussed above (De Waal Malefyt et al., 1992).
R6	Cue Arg1:T10 Arg2:T9	
T11	KT_cue 403 446	Current studies as discussed above indicate
R7	Cue Arg1:T11 Arg2:T9	
T12	CL_cue 403 446	Current studies as discussed above indicate
R8	Cue Arg1:T12 Arg2:T9	
T13	Verb_cue 403 451	Current studies as discussed above indicate that
R9	Cue Arg1:T13 Arg2:T9	
T111	Fact 452 595	IL-10 produces an anti-inflammatory effect and has the ability to act as a main suppressor of cellular immunity (De Waal Malefyt et al., 1992).
A67	Source T111 Non-integral_information_led_citation
T137	KT_cue 452 466	IL-10 produces
R87	Cue Arg1:T137 Arg2:T111	
T8	KT_cue 304 347	Clinical trials yet need to be conducted to
R5	Cue Arg1:T8 Arg2:T7	
T51	Analysis 2710 2759	Weber-Nordt    et al (1994) study identified that
A27	Verb_noun T51 Certainty
A28	Source T51 Integral_citation
A68	Certainty_Level T51 L4
T52	Source_cue 2710 2743	Weber-Nordt    et al (1994) study
R33	Cue Arg1:T52 Arg2:T51	
T53	KT_cue 2710 2754	Weber-Nordt    et al (1994) study identified
R34	Cue Arg1:T53 Arg2:T51	
T54	CL_cue 2710 2754	Weber-Nordt    et al (1994) study identified
R35	Cue Arg1:T54 Arg2:T51	
T138	Verb_cue 2710 2759	Weber-Nordt    et al (1994) study identified that
R88	Cue Arg1:T138 Arg2:T51	
T55	Observation 2760 2974	the endotoxin result in an increase in the expression of IL-10R on fibroblasts although following T cell stimulation with anti-CD3-antibodies a decrease of IL- 10R gene expression has been found (Liu et al., 1994).
A29	Source T55 Non-integral_information_led_citation
T56	KT_cue 2760 2783	the endotoxin result in
R36	Cue Arg1:T56 Arg2:T55	
T57	Source_cue 2955 2974	(Liu et al., 1994).
R37	Cue Arg1:T57 Arg2:T55	
T73	Analysis 3498 3543	Josephson et al (2001) have demonstrated that
A37	Verb_noun T73 Certainty
A38	Source T73 Integral_citation
A69	Certainty_Level T73 L4
T74	Source_cue 3498 3520	Josephson et al (2001)
R47	Cue Arg1:T74 Arg2:T73	
T75	KT_cue 3498 3538	Josephson et al (2001) have demonstrated
R48	Cue Arg1:T75 Arg2:T73	
T139	CL_cue 3498 3538	Josephson et al (2001) have demonstrated
R89	Cue Arg1:T139 Arg2:T73	
T140	Verb_cue 3498 3543	Josephson et al (2001) have demonstrated that
R90	Cue Arg1:T140 Arg2:T73	
T141	Observation 3544 3680	there was no interaction or  complexes formed between  IL-10  and the IL-  10R without the presence of both IL-10R1 and IL-10R2 present.
A70	Source T141 Integral_citation
T142	KT_cue 3544 3556	there was no
R91	Cue Arg1:T142 Arg2:T141	
T143	Fact 4287 4349	There  are  two types of Janus tyrosine Kinase, JAK1 and Tyk2.
A71	Source T143 Averred
T144	KT_cue 4287 4297	There  are
R92	Cue Arg1:T144 Arg2:T143	
T145	Fact 2538 2592	and is responsible for downstream signal transduction.
A72	Source T145 Averred
T146	KT_cue 2542 2560	is responsible for
R93	Cue Arg1:T146 Arg2:T145	
A73	Multiple_sources T51
A74	Multiple_sources T55
A76	Certainty_Level T132 L4
T147	CL_cue 7159 7200	The STAT3 protein has recently emerged as
R94	Cue Arg1:T147 Arg2:T132	
T87	Investigation 4122 4145	As previously discussed
A46	Source T87 Self_other
T88	KT_cue 4122 4145	As previously discussed
R57	Cue Arg1:T88 Arg2:T87	
T89	Fact 4146 4285	the activation IL-10 binds to the extracellular domain of receptor complex IL-10R1 and IL-10R2 which then activates Janus tyrosine  Kinase.
A77	Source T89 Averred
T148	KT_cue 4146 4172	the activation IL-10 binds
R58	Cue Arg1:T148 Arg2:T89	
